The US Food and Drug Administration got right back into the novel drug approval game after a week off, giving its go-ahead to Ardelyx Inc.'s Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C). The Center for Drug Evaluation and Research has now approved 27 novel drugs in 2019.
Another notable approval went to a non-novel product:Xeris Pharmaceuticals Inc.'s Gvoke (glucagon) for the treatment of severe hypoglycemia. Gvoke...





